Valor predictivo negativo del SPECT con Ioflupano 123I en los trastornos del movimiento

Vicente, J. Serrano; Bernardo, L. García; Barquero, C. Durán; Silva, A. Constantino; Torre, J.R. Infante de la; Grande, M.L. Domínguez; Madrid, J.I. Rayo; Sánchez, R. Sánchez; Herrera, Carmen Durán

doi:10.1016/s0212-6982(09)70207-1

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although abnormal in most patients with Parkinson's disease, a normal DaT-SPECT is not capable to totally exclude the disease (Vlaar et al, 2007, 2008; Serrano Vicente et al, 2009). A meta-analysis was conducted by Vlaar and colleagues to review the diagnostic accuracy of SPECT to differentiate between early phase of PD and normalcy.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed we diagnosed 1 case with Parkinson's disease in spite of having a normal DaT-SPECT. At least two studies found that in cases that undergo a second DaT-SPECT the accordance of the result with the final clinical diagnosis was higher in the second DaT-SPECT than in the first one (Vlaar et al, 2007, 2008; Serrano Vicente et al, 2009), thus suggesting that the result of the first DaT-SPECT of patients with Parkinson's disease can be negative if performed too early and become positive later on. In our study 4 out of 12, in which a second DaT-SPECT was performed, resulted abnormal.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study

Menéndez-González

Tavares

Zeidan

et al. 2014

Front. Aging Neurosci.

View full text Add to dashboard Cite

The [123I]ioflupane—a dopamine transporter radioligand—SPECT (DaT-SPECT) has proven to be useful in the differential diagnosis of tremor. Here, we investigate the diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT. Therefore, 30 patients with tremor and normal DaT-SPECT were followed up for 2 years. In 18 cases we were able to make a diagnosis. The residual 12 patients underwent a second DaT-SPECT, were then followed for additional 12 months and thereafter the diagnosis was reconsidered again. The final diagnoses included cases of essential tremor, dystonic tremor, multisystem atrophy, vascular parkinsonism, progressive supranuclear palsy, corticobasal degeneration, fragile X–associated tremor ataxia syndrome, psychogenic parkinsonism, iatrogenic parkinsonism and Parkinson's disease. However, for 6 patients the diagnosis remained uncertain. Larger series are needed to better establish the relative frequency of the different conditions behind these cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study

Menéndez-González

Tavares

Zeidan

et al. 2014

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…Substantial controversy exists as to whether these methods can answer these questions. (Serrano Vicente et al, 2009;Eerola et al, 2005) Many national and international meetings (like the International Movement Disorders Society) have forums for addressing these controversies. In fact, some of these methods have been approved for clinical application in other countries.…”

mentioning

confidence: 99%

Expert Testimony at the Food and Drug Administration: Who Wants the Truth?

Perlmutter¹

2011

Narrative Inquiry in Bioethics

View full text Add to dashboard Cite

I participated as an invited guest speaker at a Food and Drug Administration Advisory Panel meeting to provide expert background information on the potential clinical utility of dopaminergic neurons in the human brain. My conclusion at the end of the talk was that currently no clinical applications were justified. The purpose of the panel meeting was to advise the FDA regarding potential approval of a new drug application for a radiopharmaceutical that can be used to image dopaminergic pathways in the brain of living humans. After giving my presentation, I was permitted to observe the FDA and Pharma presentations but not permitted to ask or answer questions. This raises concerns about whether the FDA panel obtains a fair and unbiased review of the relevant data.

show abstract